Communiqués Takeda Pharmaceutical Company Limited London S.E.

Actions

0A87

US8740602052

Marché Fermé - London S.E. Autres places de cotation 17:28:45 18/06/2024			Varia. 5j.	Varia. 1 janv.
12,74 ^USD	-2,52%		-2,56%	-10,44%

05:59	Sun Pharma signe un accord avec le japonais Takeda pour commercialiser le Vonoprazan en Inde	MT
18/06	Takeda Pharmaceutical annonce que les résultats d'un essai de phase 3 confirment l'utilisation d'Hyqvia comme traitement d'entretien de la polyneuropathie inflammatoire démyélinisante chronique (PIDC)	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	19/06	BU
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	19/06	AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	18/06	AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	18/06	BU
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	17/06	PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	17/06	BU
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	14/06	BU
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	11/06	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	11/06	PU
TAKEDA PHARMACEUTICAL : Form 6 K	10/06	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	07/06	PU
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	04/06	AQ
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo	03/06	BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	31/05	BU
Takeda Pharmaceutical : Other items which are provided electronically	29/05	PU
TAKEDA PHARMACEUTICAL : Form 6-K	21/05	PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	16/05	AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	14/05	BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	13/05	BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	10/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Takeda Pharmaceutical Company Limited London S.E.

Actions

0A87

US8740602052

Communiqués

Filtres